INVO Fertility (IVF) Volume Spikes 19.8x Average as Deep Book-Value Discount Draws Attention
IVF (INVO Fertility) volume surged 19.8x average with a 0.17x price-to-book discount, but weak ROE and a Q1 EPS miss raise value-trap risk to watch.
signal:IVF:2026-08-17 INVO Fertility (IVF) Volume Spikes 19.8x Average as Deep Book-Value Discount Draws Attention
INVO Fertility (IVF) trading volume jumped to 19.8x its 20-day average on August 17, even though the day's headlines only flagged the stock among generic "most active" and "stocks in motion" lists without pointing to a specific catalyst -- a gap between the size of the move and the absence of clear news that makes the stock's 0.17x price-to-book ratio the more concrete piece of evidence worth tracking, since it prices the fertility-technology company at a steep discount to its net asset base. That combination of an unexplained volume surge and a deeply discounted book value is the core setup: whether opportunistic buying interest can build on the spike, or whether it fades once the mystery catalyst (if any) is priced in.
Key Facts
| Stock name | IVF |
|---|---|
| Ticker | IVF |
| Market | NASDAQ |
| Sector | Unclassified |
| Volume (x average) | 19.8x |
| Signal price | $1.53 |
INVO Fertility, Inc. is a healthcare services company operating in the fertility marketplace, providing assisted reproductive technology care through two segments: Fertility Clinic Services and the INVOcell Device business. Its flagship INVOcell device enables fertilization and early embryo development to occur in vivo within the patient's body, and the company also operates fertility clinics under the INVO Centers brand. Formerly known as NAYA Biosciences, Inc., the company adopted its current name in April 2025 and is headquartered in Sarasota, Florida.
Recent Analyst Coverage
External analyst opinions (not investment advice): (2026-08-01)
| Strong Buy | 1 |
|---|---|
| Buy | 3 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
Peer Companies
BMRA, NUWE, BJDX, XAIR, FEED
Risk Factors
The valuation discount comes with a corresponding red flag: return on equity of -57.2% alongside a 57% debt ratio points to a capital structure under strain, and the most recent quarter (ended 2026-03-31) missed EPS estimates by -167.7% (actual -3.38 vs. expected -1.2625). A negative EV/EBITDA of -0.6x confirms the company is currently earnings-negative rather than simply cheap, which is the classic setup for a value trap -- a low PBR that reflects deteriorating fundamentals rather than a mispriced opportunity.
The macro backdrop adds a further headwind for a name in this financial condition: the US 10-year Treasury yield has climbed to 4.72%, up 0.13 percentage points over the past month, a rising-rate trend that typically pressures unprofitable small-cap issuers with weak balance sheets more than the broader market. VIX at 15.2 sits in a normal range and offers no particular tailwind or warning signal either way, so the yield trend is the more relevant macro variable to watch alongside company-specific execution.
Recent Disclosures
Recent News
- 2026-08-17 Which stocks are moving after the closing bell on Monday?
- 2026-08-17 Let's take a look at the stocks that are in motion in today's session.
- 2026-08-17 Which stocks are most active on Monday?
Earnings Trend
| Fiscal Year | Revenue | Net Income |
|---|---|---|
| 2023 | $3M | $-8M |
| 2024 | $7M | $-9M |
| 2025 | - | $-23M |
Pre-Trade Checklist
| Business & competitive edge understood | ✅ Company profile summarized above |
|---|---|
| Leading sector | ⚠️ Not flagged as a leading sector |
| Good news already priced in? | ⚠️ 밸류트랩 후보(저평가 지표 대비 ROE/부채비율 약함 — 구조적 하락 가능성 점검 필요) |
| Stop-loss / take-profit set | ✅ Stop-loss -10% / first take-profit +20% set in advance |
| Exit plan if wrong | ✅ 10% trailing stop from peak; setup auto-invalidated on a break below key support |
Trade Levels
| Signal price | $1.53 |
|---|---|
| Stop-loss | $1.38 (-10% from signal price) |
| First take-profit | $1.84 (+20% from signal price) |
| Trailing stop | 10% from peak |
| Invalidation | Close back below key support ($1.07) |
With shares trading near the $1.53 signal price, the setup to monitor calls for a stop-loss at $1.38 and an initial take-profit target at $1.84, with a 10% trailing stop from any peak reached beyond that; a close back below the $1.07 support level would undercut the thesis entirely. Given the value-trap warning signs sitting alongside the deep PBR discount, this remains a name to watch for confirmation of follow-through buying rather than one to chase on the volume spike alone.